Skip to main content

Table 1 Comparison of baseline characteristics between the DP and no-DP groups among patients with IPF

From: Blood Krebs von den Lungen-6 levels predict treatment response to antifibrotic therapy in patients with idiopathic pulmonary fibrosis

 

Total

DP

no-DP

P-value

Number of patients

188

43

145

 

Age, year

68.9 ± 7.7

71.2 ± 7.1

68.3 ± 7.7

0.025

Male sex

146 (77.7)

33 (76.7)

113 (77.9)

0.870

Ever-smoker

144 (76.6)

32 (74.4)

112 (77.2)

0.701

BMI, kg/m2

24.5 ± 3.3

23.3 ± 3.8

24.9 ± 3.1

0.011

Pulmonary function test

    

 FVC, % predicted

74.7 ± 17.0

69.1 ± 19.3

76.4 ± 15.9

0.013

 DLco, % predicted

58.4 ± 18.5

57.0 ± 21.9

58.8 ± 17.4

0.601

 TLC, % predicted

73.6 ± 13.6

70.7 ± 17.3

74.4 ± 12.3

0.196

6-minute walk test

    

 Distance, m

431.4 ± 109.9

377.9 ± 135.7

447.7 ± 95.6

0.005

 Lowest SpO2, %

89.6 ± 6.3

88.7 ± 6.4

89.8 ± 6.2

0.309

KL-6, U/mL

1039.7 ± 823.7

1101.9 ± 955.2

1021.3 ± 783.3

0.574

  1. Data are presented as mean ± standard deviation or number (%)
  2. DP: disease progression; IPF: idiopathic pulmonary fibrosis; BMI: body mass index; FVC: forced vital capacity; DLco: diffusing capacity of the lung for carbon monoxide; TLC: total lung capacity; and KL-6: Krebs von den Lungen-6